MNTA has more moving parts than any sub-$1B biotech company I have ever encountered, which is probably seen as a negative by some investors. Anything that makes the package more digestible is a step in the right direction.
p.s. The company’s complexity is the reason I maintain the ‘ReadMeFirst’ primer and update it often.
Market Data 
Markets 
AI
